During a Case-Based Roundtable® event, Julie R. Brahmer, MD, MSC, reviewed the CheckMate 9LA, KEYNOTE-407, and POSEIDON ...
Panelists discuss how clinicians can effectively manage patients with high-risk myelofibrosis with cytopenias through careful treatment selection, dose modification strategies, and monitoring of ...
Panelists discuss how complex cases of advanced myelofibrosis can be managed using evidence-based treatment algorithms, considering factors such as disease progression, prior therapies, and ...
The FDA makes furthering moves in SCLC, ovarian, and breast cancers, and the value of remote clinical pharmacists is explored in community oncology.
Tivozanib plus nivolumab had similar patient-reported outcomes to tivozanib alone in advanced kidney cancer after prior ...
Orca-T with reduced-intensity stem cell transplantation was a safe, feasible alternative to conventional transplant in blood ...
Belzutifan plus cabozantinib maintained durable antitumor activity in advanced clear cell renal cell carcinoma, per phase 3 ...
Vimseltinib is now an FDA-approved treatment for patients with tenosynovial giant cell tumor, based on findings from the ...
The off-the-shelf chimeric antigen receptor T-cell therapy P-BCMA-ALLO1 was shown to be safe and elicited strong anti-tumor ...
The addition of 177Lu-PSMA-617 to enzalutamide significantly improved overall survival and QOL in patients with metastatic ...
A phase 2 study evaluated the use of ruxolitinib plus standard GVHD prophylaxis in patients with myelofibrosis undergoing ...
During a Case-Based Roundtable® event, Muhammad Umair Mushtaq, MD, discussed managing long-term toxicity concerns related to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback